| Abhay J Dhond, MD | |
|
1450 Chapel St., New Haven, CT 06511-4405 | |
| (203) 789-4044 | |
| (203) 789-3007 |
| Full Name | Abhay J Dhond |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 41 Years |
| Location | 1450 Chapel St., New Haven, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669424669 | NPI | - | NPPES |
| 001850969 | Medicaid | PA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Medical Group Inc | 1254233836 | 1251 |
News Archive
Data published in the March issue of the Annals of Surgery show that investigational use of sacral nerve stimulation with Medtronic InterStim® Therapy reduces fecal incontinent episodes and increases quality of life in patients with the condition. The 120-patient, multi-center study - the largest trial of its kind in the world and the first such trial in North America - examined the efficacy of InterStim Therapy in patients with chronic fecal incontinence who had failed or were not candidates for more conservative treatments.
"The Millennium Challenge Corporation (MCC), through its partnership with the Millennium Challenge Account-Lesotho, is helping Lesotho address key challenges in its health sector through a $122 million investment in health infrastructure and health systems," IIP Digital reports.
Harvard University and Dana-Farber Cancer Institute announced today that they have concluded a major licensing agreement with Acetylon under which Harvard and Dana-Farber granted an exclusive therapeutic license to a robust platform technology and chemical methodology that enables high-throughput screening and lead optimization for HDAC inhibitor compounds.
An increase in the incidence and mortality rate of cancer has been noted worldwide, especially for lung cancer.
› Verified 6 days ago
| Entity Name | Cornell Scott Hill Health Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902921380 PECOS PAC ID: 3072418359 Enrollment ID: O20031201000145 |
News Archive
Data published in the March issue of the Annals of Surgery show that investigational use of sacral nerve stimulation with Medtronic InterStim® Therapy reduces fecal incontinent episodes and increases quality of life in patients with the condition. The 120-patient, multi-center study - the largest trial of its kind in the world and the first such trial in North America - examined the efficacy of InterStim Therapy in patients with chronic fecal incontinence who had failed or were not candidates for more conservative treatments.
"The Millennium Challenge Corporation (MCC), through its partnership with the Millennium Challenge Account-Lesotho, is helping Lesotho address key challenges in its health sector through a $122 million investment in health infrastructure and health systems," IIP Digital reports.
Harvard University and Dana-Farber Cancer Institute announced today that they have concluded a major licensing agreement with Acetylon under which Harvard and Dana-Farber granted an exclusive therapeutic license to a robust platform technology and chemical methodology that enables high-throughput screening and lead optimization for HDAC inhibitor compounds.
An increase in the incidence and mortality rate of cancer has been noted worldwide, especially for lung cancer.
› Verified 6 days ago
| Entity Name | Northeast Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043278351 PECOS PAC ID: 1254233836 Enrollment ID: O20040123000522 |
News Archive
Data published in the March issue of the Annals of Surgery show that investigational use of sacral nerve stimulation with Medtronic InterStim® Therapy reduces fecal incontinent episodes and increases quality of life in patients with the condition. The 120-patient, multi-center study - the largest trial of its kind in the world and the first such trial in North America - examined the efficacy of InterStim Therapy in patients with chronic fecal incontinence who had failed or were not candidates for more conservative treatments.
"The Millennium Challenge Corporation (MCC), through its partnership with the Millennium Challenge Account-Lesotho, is helping Lesotho address key challenges in its health sector through a $122 million investment in health infrastructure and health systems," IIP Digital reports.
Harvard University and Dana-Farber Cancer Institute announced today that they have concluded a major licensing agreement with Acetylon under which Harvard and Dana-Farber granted an exclusive therapeutic license to a robust platform technology and chemical methodology that enables high-throughput screening and lead optimization for HDAC inhibitor compounds.
An increase in the incidence and mortality rate of cancer has been noted worldwide, especially for lung cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Abhay J Dhond, MD 226 Mill Hill Ave, 3rd Floor, Bridgeport, CT 06610-2826 Ph: (203) 789-4044 | Abhay J Dhond, MD 1450 Chapel St., New Haven, CT 06511-4405 Ph: (203) 789-4044 |
News Archive
Data published in the March issue of the Annals of Surgery show that investigational use of sacral nerve stimulation with Medtronic InterStim® Therapy reduces fecal incontinent episodes and increases quality of life in patients with the condition. The 120-patient, multi-center study - the largest trial of its kind in the world and the first such trial in North America - examined the efficacy of InterStim Therapy in patients with chronic fecal incontinence who had failed or were not candidates for more conservative treatments.
"The Millennium Challenge Corporation (MCC), through its partnership with the Millennium Challenge Account-Lesotho, is helping Lesotho address key challenges in its health sector through a $122 million investment in health infrastructure and health systems," IIP Digital reports.
Harvard University and Dana-Farber Cancer Institute announced today that they have concluded a major licensing agreement with Acetylon under which Harvard and Dana-Farber granted an exclusive therapeutic license to a robust platform technology and chemical methodology that enables high-throughput screening and lead optimization for HDAC inhibitor compounds.
An increase in the incidence and mortality rate of cancer has been noted worldwide, especially for lung cancer.
› Verified 6 days ago
Dr. Brian Christopher Cambi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 333 Cedar St, Dcb 3, New Haven, CT 06510 Phone: 203-785-4129 Fax: 203-737-2437 | |
Ms. Maryam Gondal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 330 Cedar Street, Bb 114, New Haven, CT 06510 Phone: 203-785-4184 | |
Matthew Joseph Mcconnell, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 333 Cedar St, Ynhh Internal Medicine-gi,section Of Digestive Diseases, New Haven, CT 06510 Phone: 203-785-7012 | |
Marie Anjeliese Rodriguez, Internal Medicine Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Dr. Margaret M Xu, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Carola Marte, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1450 Chapel St, Haelen Center, New Haven, CT 06511 Phone: 203-789-4135 Fax: 203-867-5241 | |
Jeanette M Tetrault, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Long Wharf Dr, New Haven, CT 06511 Phone: 203-781-4600 Fax: 203-781-4624 |